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Invasive cervix cancer (ICC) is the third most common malignant tumor in women and
human papillomavirus 16 (HPV16) causes more than 50% of ICC. DNA methylation
is a covalent modification predominantly occurring at CpG dinucleotides and increased
methylation across the HPV16 genome is strongly associated with ICC development. Next
generation (Next Gen) sequencing has been proposed as a novel approach to determine
DNA methylation. However, utilization of this method to survey CpG methylation in the
HPV16 genome is not well described. Moreover, it provides additional information on
methylation “haplotypes.” In the current study, we chose 12 random samples, amplified
multiple segments in the HPV16 bisulfite treated genome with specific barcodes,
inspected the methylation ratio at 31 CpG sites for all samples using Illumina sequencing,
and compared the results with quantitative pyrosequencing. Most of the CpG sites
were highly consistent between the two approaches (overall correlation, r = 0.92), thus
verifying that Next Gen sequencing is an accurate and convenient method to survey
HPV16 methylation and thus can be used in clinical samples for risk assessment.
Moreover, the CpG methylation patterns (methylation haplotypes) in single molecules
identified an excess of complete-and non-methylated molecules and a substantial amount
of partial-methylated ones, thus indicating a complex dynamic for the mechanisms of
HPV16 CpG methylation. In summary, the advantages of Next Gen sequencing compared
to pyrosequencing for HPV genome methylation analyses include higher throughput,
increased resolution, and improved efficiency of time and resources.
Keywords: human papillomavirus, methylation, next generation sequencing, CpG methylation, methylation
haplotypes
INTRODUCTION
Invasive cervical cancer (ICC) is the third most common malig-
nant tumor in women and is caused by persistent infection of
oncogenic human papillomavirus (HPV) (Jemal et al., 2011),
especially type 16, which accounts for greater than 50% of all
ICC (Schiffman et al., 2007; Li et al., 2011; Schiffman and
Wentzensen, 2013). Recent data indicates that multiple regions of
HPV16 and other oncogenic HPV type genomes show increasing
CpG methylation patterns among normal, cervical intraepithe-
lial neoplasia (CIN), and cancer tissues, respectively (Badal et al.,
2003; Kalantari et al., 2004, 2009, 2010, 2014; Hong et al., 2008;
Brandsma et al., 2009, 2014; Ding et al., 2009; Fernandez et al.,
2009; Fernandez and Esteller, 2010; Piyathilake et al., 2011; Sun
et al., 2011;Wentzensen et al., 2012; Lorincz et al., 2013;Mirabello
et al., 2013). Thus, assays for quantitation of CpG methylation
of oncogenic HPV genomes in general and HPV16 in particu-
lar, indicate that methylation is a promising biomarker for ICC
development (Clarke et al., 2012). Therefore, a fast, accurate,
and high-throughput approach to survey DNA methylation
in HPV16 should facilitate ICC prevention, diagnosis, and
treatment.
So far, the most widely used method for HPV DNA methy-
lation investigation is bisulfite treatment followed by sequencing
(Bhattacharjee and Sengupta, 2006), MassArray (Ehrich et al.,
2005), SNPshot (Kaminsky and Petronis, 2009), or in particular
pyrosequencing (Tost and Gut, 2007a,b; Dejeux et al., 2009) (for
review, see Clarke et al., 2012). Despite the accuracy of CpG quan-
titation by pyrosequencing, it can only provide a relatively short
read for each assay per sample and thus is time and labor inten-
sive for testing multiple sites in large numbers of samples, which
limits the incorporation of DNA methylation in clinical studies.
Moreover, all these approaches constrain the ability to detect the
methylation pattern at single-DNA-molecule resolution, which is
critical for investigating methyltransferase dynamics. Although
the cloning-sequencing approach after bisulfite treatment can
provide some insight into this issue, the typically low num-
ber of clones analyzed (<10) and the high costs limits this
approach.
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Next generation sequencing can yield millions of single
molecule reads and has been used to determine DNA methyla-
tion (Taylor et al., 2007; Bibikova and Fan, 2010; Laird, 2010; Feng
et al., 2011; Kim et al., 2011; Komori et al., 2011; Ku et al., 2011;
Nejman et al., 2014). Supplemented with DNA barcoding tech-
nology, which incorporates a unique index sequence into each
PCR segment, this approach can provide a rapid way to simulta-
neously determine DNA methylation at the single-molecule level
in large numbers of samples. However, the accuracy and valid-
ity of this approach needs further evaluation, especially in viral
genomes such as HPV16.
In the present study, we randomly chose 12 samples with
quantitation of CpG methylation within the HPV16 genome
by pyrosequencing and performed amplification with primers
containing barcodes specific for each sample. After all sam-
ples were pooled and purified, the PCR products were deep
sequenced, analyzed, and the results were compared with CpG
methylation determined by pyrosequencing. The methylation
ratio for most CpG sites was highly correlated with those
from pyrosequencing, which indicated that Next Gen sequenc-
ing of bisulfite treated cervical cells infected with HPV16 was
an accurate method of quantitating CpG methylation. Moreover,
the single molecule analyses provides a “methylation haplo-
type” and indicated an excess of full and non-methylated
molecules in nearly all samples and a lower proportion of
partially methylated molecules in most samples, thus reveal-
ing a complex and mosaic methylation pattern in the HPV16
genome.
MATERIALS AND METHODS
CERVICOVAGINAL SAMPLES
Twelve exfoliated cervical samples were randomly chosen from a
previously reported nested case-control study of HPV16-positive
cervical intraepithelial neoplasia grade 3 (CIN3) and HPV16-
positive cervical samples that cleared infection (Mirabello et al.,
2012). The lab was blinded to all clinical information. All sam-
ples contained HPV16 and the quantitation of CpG methylation
of the HPV16 genome had been determined by pyrosequencing,
as described (Mirabello et al., 2012). The study was designed to
test samples for quantitation of CpGmethylation to evaluate Next
Gen sequencing compared to pyrosequencing prior to embark-
ing on using this method on precious well-characterized samples
from epidemiological studies.
ASSAY DESIGN
Since L1, L2, and E2 ORF regions showed differential methyla-
tion among disease groups (Mirabello et al., 2012), these three
regions and the most significant CpG sites within them were
chosen for the current study. Primers for PCR were designed
using MethPrimer (Li and Dahiya, 2002) (http://www.urogene.
org/methprimer/index1.html). In total, 3 segments in L1, 4 in L2,
and 1 in E2 were included in the current study (Table 1A), and in
total, 31 CpG sites were surveyed. Each primer was labeled by a
unique barcode and 5′ and 3′ padding sequence (Table 1B) and
synthesized by Integrated DNA Technologies (IDT, Coralville,
IA). A map of all 112 CpG sites in the HPV16 7906 bp reference
genome is shown in Figure 1 in the review by Clarke et al. (2012).
Table 1A | Next Gen sequencing assays of bisulfite treated HPV16
DNA in clinical samples.
Assay name #CpG CpG position Length (bp)
L1_1 4 5602, 5608, 5611, 5617 114
L1_2 4 7034, 7091, 7136, 7145 172
L1_7 2 6650, 6581 167
L2_1 5 4240, 4249, 4261, 4270,
4277
130
L2_2 3 4427, 4437, 4441 89
L2_4 3 5128, 5173, 5179 123
L2_5 1 5378 166
E2_1 5 3412, 3415, 3417, 3433,
3436 (3448, 3462, 3473,
3496)
169
( ), These sites were present in the NGS data but not PSQ.
Table 1B | Description of barcoded primers* for assays shown in this
table.
Primer 5′ pad 3′ pad Primer target
name (LP) (RP) sequence (5′-3′)
16E2_1F ACT GCAG TTAGGTAGTATTTGGTTAATTATTT
16E2_1R ACT GCAG ATTAAAACACTATCCACTAAATCTCTATAC
16L1_1F TAC GTAC TAATATATAATTATTGTTGATGTAGGTGAT
16L1_1R TAC GTAC AACAACCAAAAAAACATCTAAAAAA
16L1_2F ACT GACG TTTGTAGATTTAGATTAGTTTTTTTTAGGA
16L1_2R ACT GACG TTCAACATACATACAATACTTACAACTTAC
16L1_7F TAC GATG ATGTAGTTTTTGAAGTAGATATGGTAGTA
16L1_7R TAC GATG AATTACCTCTAATACCCAAATATTCAA
16L2_1F ATC GACG TTTTTGTTTGTTTGTTTGTTTTT
16L2_1R ATC GACG ACATATACCTACCTATTTACATATTTTATA
16L2_2F ATC GACG TATGGAAGTATGGGTGTATTTTT
16L2_2R ATC GACG ATTCCCAATAAAATATACCCAATAC
16L2_4F ATC GTAC TTTTGGATATAGTTGTTTTATATAGGTTAG
16L2_4R ATC GTAC CCTTAACACCTATAAATTTTCCACTAC
16L2_5F ATC GTCA TTGTAGAAGAAATAGAATTATAAATTATAA
16L2_5R ATC GTCA AAAAATATAAAAAATACAAATAATACC
*Each primer consisted of 5′ to 3′: 3 bp (LP) – 8 bp Barcode – 4 bp (RP) – Primer
Target Sequence.
BISULFITE TREATMENT, PCR, PURIFICATION, AND DEEP SEQUENCING
DNA samples containing HPV16 DNA were treated with freshly
prepared bisulfite using the EZ DNA methylation kit (Zymo
Research, Orange, CA) according to the manufacturer’s proto-
col. Upon bisulfite treatment, unmethylated C’s are converted
into U’s, which are then converted to T’s by Taq polymerase
during PCR amplification; methylated C’s remain unmodified.
Thus, in the CpG sequence a “C” represents a methylated CpG,
whereas a “T” represents an unmethyaled CpG. All segments were
amplified by HotStart-IT FideliTaq DNA polymerase (United
States Biochemicals, Cleveland, OH). After validating size and
intensity in a 3% agarose gel, each PCR product was pooled
in equal proportions, separated by electrophoresis, and isolated
from the gel. After precipitation by isopropanol and washed
by 70% ethanol, the PCR products were ligated with adaptor
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FIGURE 1 | The summary correlation of 27 CpG methylation sites between pyrosequencing and Next Gen sequencing. The x-axis is percent
methylation by pyrosequencing and the y-axis is percent methylation by Next Gen sequencing. Each CpG site is plotted for each subject.
(library construction) and sequenced on an Illumina HiSeq 2000
(NG sequencing) within the Albert Einstein College of Medicine,
Epigenetics Core Facility (Bronx, NY).
METHYLATION RATIO ANALYSIS
The obtained sequences were filtered by prinseq (Schmieder and
Edwards, 2011) with average Phred score (Cock et al., 2010) not
less than 20. The barcodes for each sample were split and cut
by FastX kit (http://hannonlab.cshl.edu/fastxtoolkit/index.html).
After alignment with the reference HPV16 genome by bowtie
(Langmead et al., 2009), the methylation status for each molecule
was determined by Bismark (Krueger and Andrews, 2011). For
each CpG site, the methylation ratio is calculated by the for-
mula: number of C reads divided by the sum of C and T reads
at each CpG site. The pyrosequencing result for each site was
determined on a PSQ96 ID Pyrosequencer (Qiagen, Valencia,
CA) at the Albert Einstein College of Medicine, Genomics Core
Facility (Bronx, NY) and the readout was percent methylation,
as previously described (Mirabello et al., 2012). The correlation
between NG sequencing and pyrosequencing was performed by
linear regression in SPSS 16.0 (SPSS Inc., Chicago, IL) and the
null hypothesis was rejected when P < 0.05. We have deposited
the read sequences in the NCBI Sequence Read Archive (SRA)
database, accession number SRP040981.
SINGLE MOLECULE ANALYSIS
The methylation pattern for each single molecule and the counts
of each pattern were obtained by an in-house script (available
on request). Briefly, the Bismark output, which gave the methy-
lation state for each CpG site in each molecule, was parsed, and
the methylation pattern of each DNA molecule was then recon-
structed based on the unique read name it was assigned by the
sequencer. Finally, the prevalence of each uniquemethylation pat-
tern was counted, for each sample in each assay. The expected
probabilities were constructed in two steps. First the singular
probabilities of each site beingmethylated and unmethylated were
calculated, by counting the proportions of molecules in each
state at each site. Multiplying the appropriate singular probabil-
ities, under the assumption that CpG sites would be methylated
independently, produced an expected probability for each methy-
lation pattern. A χ2 goodness of fit test was then performed to
compare observed and expected probabilities formethylation pat-
terns, where the observed probabilities were the proportions of
each detected pattern, calculated from their counts.
RESULTS
SEQUENCING DATA STATISTICS
In total, 192.2 million reads 95 bp long were obtained from NG
sequencing and 53.4 million (27.8%) possessed an average Phred
score above 20 and were used for this analysis (Ewing and Green,
1998). 41.7 million reads (78.1%) were observed to contain one
of the incorporated barcodes without mismatch and assigned to a
corresponding sample for further analysis. Except one segment in
the L2 gene, most segments included ∼4–8 million reads (Figure
S1A). For each sample, the read count varied from 2 to 6 million
(Figure S1B). Most CpG sites (21/27) were covered by 0.6 to 1.8
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million reads (Figure S1C), in total. Although three fragments did
not amplify as robustly and had less reads (i.e., L1_2, L2_2, and
L2_5 assays containing CpG sites 7034, 7091, 7136, 7145; 4427,
4437, 4441; and 5378, respectively), the correlation between CpG
sites within these fragments between the PSQ and NGS assays had
reasonable agreement (see Figure 2).
METHODOLOGICAL COMPARISON
Among these 31 CpG sites, 27 had been analyzed by pyrose-
quencng and the two results were compared. Using linear regres-
sion, most sites showed significant correlation between the two
methods with an overall correlation of 0.92 (Figure 1). Only
two CpG sites (positions 6650 and 7034) were poorly correlated
(P = 0.069 and 0.19, respectively, Figure 2). These results indi-
cated that next generation sequencing was an appropriate method
for determining CpG methylation in the HPV16 genome, yield-
ing results that were highly correlated with a well-established
pyrosequencing technique.
SINGLE-MOLECULE RESOLUTION OF CPG METHYLATION
The methylation pattern for each single molecule was deter-
mined for each sample across six regions of the HPV16 genome.
A substantial proportion (10–80%) of molecules in the six assays
were partially methylated (possessing a mixture of methylated
and unmethylated sites), and the distributions of patterns were
varied. However, the site-wise proportions of methylation for
a given sample in a given assay were similar and the distribu-
tion of patterns in each molecule did exhibit dependence on
that methylation level. To address this issue, we calculated the
expected frequencies of all possible methylation patterns in each
assay and compared them with the observed patterns (Figure 3).
In most samples, a relative excess of none- and/or fully methy-
lated molecules was observed (Figure 3). In contrast, despite their
high prevalences, there was a relative absence of partial methy-
latedmolecules (Figure 3). As a consequence, most of the samples
yielded a significant P-value (p < 0.05), thus indicating that CpG
sites are not likely to be methylated/demethylated in an indepen-
dent fashion, but that a more complex process determines the
methylation state within a region of the HPV16 genome.
DISCUSSION
In the present study, we used Illumina Next Gen single molecule
sequencing to survey the methylation of the HPV16 genome in
12 samples and compared the result with pyrosequencing, which
provides an average percent methylation for each CpG site. A con-
sequence of using Next Gen sequencing technology was the ability
to investigate the methylation pattern at the single-molecule level.
Our results demonstrate that the Next Gen bisulfite sequencing
protocol was comparable to the well-established pyrosequencing-
based method for assaying HPV16 genome methylation (over-
all correlation = 0.92). The ability to analyze single molecules
allowed us to test whether the process of CpG methylation at
specific sites was independent. Thus with known percent CpG
methylation at each site we compared the observed with the
predicted methylation haplotypes. There was a significant dif-
ference indicating that CpG methylation of multiple CpG sites
on a given fragment of the viral genome is not an independent
process. In addition, utilizing DNA barcoding, multiple samples
FIGURE 2 | The correlation of 27 individual CpG methylation sites
between pyrosequencing and Next Gen sequencing. Each plot displays
one CpG site and the location is indicated at the top. The x-axis indicates
Illumina sequencing, the y-axis pyrosequencing for percent methylation.
can be pooled together and run in a single sequencing reaction
and the result for each single sample can be distinguished without
ambiguity. Thus, the high-throughput nature of this technique
facilitates large-scale clinical and epidemiological studies.
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Several CpG sites presented a relatively low read count com-
pared with others. A careful inspection indicated that these were
located in the middle of the amplicon and would thus appear
at the end of the read in both strand. These end regions usually
have a low base call quality, due to constraints of the sequencing
technology and are, therefore, often filtered out prior to analysis.
The Bismark-based analysis method utilized in this study doesn’t
exploit the gain in base call quality that can be obtained by
comparing overlapping regions of paired-end reads, therefore
the latter problem could be surmounted by improvements
FIGURE 3 | Continued
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FIGURE 3 | The distribution of the differences between observed and
expected frequencies for each “methylation haplotype” in assay L1_1
(A), L1_7 (B), L2_1 (C), L2_2 (D), L2_4 (E), and E2_1 (F). Each boxplot
indicate one “methylation haplotype” combination. The green and red bars
denote positive and negative value, respectively. (A) “Methylation haplotype”
frequency differences in assay L1_1. (B) “Methylation haplotype” frequency
differences in assay L1_7. (C) “Methylation haplotype” frequency differences
in assay L2_1. (D) “Methylation haplotype” frequency differences in assay
L2_2. (E) “Methylation haplotype” frequency differences in assay L2_4. (F)
“Methylation haplotype” frequency differences in assay E2_1.
in the bioinformatics pipeline. Alternatively, we could shorten
the amplicon, or generate longer reads, to facilitate equal read
counts for all sites in an assay. However, there are limitations on
shortening or lengthening the amplicons, due to the composition
of sequences surrounding CpG sites that are used for the primers.
Nevertheless, it is anticipated that with advances in Next Gen
sequencing technologies longer fragment reads and improved
quality will facilitate the use of the methods described in this
report.
Despite the high consistency between next generation
sequencing and pyrosequencing results, two CpG sites, 6650 and
7034, failed to yield a significant correlation. Both CpG sites had a
relatively high read count (>1.14 and 0.15 million, respectively),
thus indicating that the low correlation was not due to stochastic
effects. A detailed audit identified one sample showing remark-
able discrepancy between the two approaches in both CpG sites
(see red circle in Figure 2). When this sample was removed from
analysis, significant correlations were obtained for both CpG
sites (r2 = 0.85, P = 0.00006 for 6650 and r2 = 0.76, P = 0.001
for 7034), which further verified the strong consistency between
the two approaches. However, the reason for the discrepancy in
this sample remains unclear. Possibilities include a nucleotide
variation at this position, which would skew the results, and/or
bisulfite- and PCR-induced artifacts. In addition, potential PCR
biases could also result in lower than expected read numbers.
Examining methylation patterns on individual molecules of
DNA is essential to understand the methyltransferase dynamics
and the mechanism(s) by which methylation interacts with
oncogenic HPV viral natural history and progression to cervi-
cal cancer. Based on cloning approaches, most previous stud-
ies suggested that methylation in promoter regions was more
likely to be one (fully methylated) or zero (fully unmethy-
lated) in human genomic DNA (Oates et al., 2006) and
HPV genomes (Kalantari et al., 2004, 2009, 2010; Turan
et al., 2006, 2007; Ding et al., 2009; Fernandez et al., 2009).
However, due to the low number of single molecules ana-
lyzed (i.e., clones sequenced), the real composition might
be substantially different. Next Gen sequencing, which can
survey millions of molecules at the same time, can pro-
vide more insight into this issue. In our results, despite
the relative excess of fully methylated and fully unmethy-
lated molecules, a substantial proportion of molecules dis-
played a partial methylation pattern, which verified previous
observations (Taylor et al., 2007) and hinted at the com-
plex regulation of the methylation process. Whether there are
dynamic changes in CpG methylation patterns remains to be
determined.
ACKNOWLEDGMENTS
This work was supported in part by the National Cancer Institute
(CA78527) (Robert D. Burk), the Einstein-Montefiore Center for
AIDS funded by the NIH (AI-51519) and the Einstein Cancer
Research Center (P30CA013330) from the National Cancer
Institute.
Frontiers in Genetics | Epigenomics and Epigenetics June 2014 | Volume 5 | Article 150 | 6
Sun et al. NGS HPV DNA methylation analyses
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fgene.
2014.00150/abstract
REFERENCES
Badal, V., Chuang, L. S., Tan, E. H., Badal, S., Villa, L. L., Wheeler, C. M.,
et al. (2003). CpG methylation of human papillomavirus type 16 DNA in
cervical cancer cell lines and in clinical specimens: genomic hypomethyla-
tion correlates with carcinogenic progression. J. Virol. 77, 6227–6234. doi:
10.1128/JVI.77.11.6227-6234.2003
Bhattacharjee, B., and Sengupta, S. (2006). CpG methylation of HPV 16 LCR at E2
binding site proximal to P97 is associated with cervical cancer in presence of
intact E2. Virology 354, 280–285. doi: 10.1016/j.virol.2006.06.018
Bibikova, M., and Fan, J. B. (2010). Genome-wide DNA methylation profiling.
Wiley Interdiscip. Rev. Syst. Biol. Med. 2, 210–223. doi: 10.1002/wsbm.35
Brandsma, J. L., Harigopal, M., Kiviat, N. B., Sun, Y., Deng, Y., Zelterman, D.,
et al. (2014). Methylation of twelve CpGs in human papillomavirus type 16
(HPV16) as an informative biomarker for the triage of women positive for
HPV16 infection. Cancer Prev. Res. (Phila.) 7, 526–533. doi: 10.1158/1940-
6207.CAPR-13-0354
Brandsma, J. L., Sun, Y., Lizardi, P. M., Tuck, D. P., Zelterman, D., Haines, G.
K. 3rd., et al. (2009). Distinct human papillomavirus type 16 methylomes in
cervical cells at different stages of premalignancy. Virology 389, 100–107. doi:
10.1016/j.virol.2009.03.029
Clarke, M. A., Wentzensen, N., Mirabello, L., Ghosh, A., Wacholder, S., Harari, A.,
et al. (2012). Human papillomavirus DNAmethylation as a potential biomarker
for cervical cancer. Cancer Epidemiol. Biomarkers Prev. 21, 2125–2137. doi:
10.1158/1055-9965.EPI-12-0905
Cock, P. J., Fields, C. J., Goto, N., Heuer, M. L., and Rice, P. M. (2010). The Sanger
FASTQ file format for sequences with quality scores, and the Solexa/Illumina
FASTQ variants. Nucleic Acids Res. 38, 1767–1771. doi: 10.1093/nar/gkp1137
Dejeux, E., El abdalaoui, H., Gut, I. G., and Tost, J. (2009). Identification and quan-
tification of differentially methylated loci by the pyrosequencing technology.
Methods Mol. Biol. 507, 189–205. doi: 10.1007/978-1-59745-522-0_15
Ding, D. C., Chiang, M. H., Lai, H. C., Hsiung, C. A., Hsieh, C. Y., and Chu, T.
Y. (2009). Methylation of the long control region of HPV16 is related to the
severity of cervical neoplasia. Eur. J. Obstet. Gynecol. Reprod. Biol. 147, 215–220.
doi: 10.1016/j.ejogrb.2009.08.023
Ehrich, M., Nelson, M. R., Stanssens, P., Zabeau, M., Liloglou, T., Xinarianos, G.,
et al. (2005). Quantitative high-throughput analysis of DNA methylation pat-
terns by base-specific cleavage and mass spectrometry. Proc. Natl. Acad. Sci.
U.S.A. 102, 15785–15790. doi: 10.1073/pnas.0507816102
Ewing, B., and Green, P. (1998). Base-calling of automated sequencer traces using
phred. II. Error probabilities. Genome Res. 8, 186–194. doi: 10.1101/gr.8.3.175
Feng, S., Rubbi, L., Jacobsen, S. E., and Pellegrini, M. (2011). Determining DNA
methylation profiles using sequencing. Methods Mol. Biol. 733, 223–238. doi:
10.1007/978-1-61779-089-8_16
Fernandez, A. F., and Esteller, M. (2010). Viral epigenomes in human tumorigene-
sis. Oncogene 29, 1405–1420. doi: 10.1038/onc.2009.517
Fernandez, A. F., Rosales, C., Lopez-Nieva, P., Grana, O., Ballestar, E., Ropero,
S., et al. (2009). The dynamic DNA methylomes of double-stranded DNA
viruses associated with human cancer. Genome Res. 19, 438–451. doi:
10.1101/gr.083550.108
Hong, D., Ye, F., Lu, W., Hu, Y., Wan, X., Chen, Y., et al. (2008). Methylation status
of the long control region of HPV 16 in clinical cervical specimens. Mol. Med.
Rep. 1, 555–560. doi: 10.3892/mmr.1.4.555
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman D. (2011). Global
cancer statistics. CA Cancer J. Clin. 61, 69–90. doi: 10.3322/caac.20107
Kalantari, M., Calleja-Macias, I. E., Tewari, D., Hagmar, B., Lie, K., Barrera-Saldana,
H. A., et al. (2004). Conserved methylation patterns of human papillomavirus
type 16 DNA in asymptomatic infection and cervical neoplasia. J. Virol. 78,
12762–12772. doi: 10.1128/JVI.78.23.12762-12772.2004
Kalantari, M., Chase, D. M., Tewari, K. S., and Bernard, H. U. (2010).
Recombination of human papillomavirus-16 and host DNA in exfoliated
cervical cells: a pilot study of L1 gene methylation and chromosomal integra-
tion as biomarkers of carcinogenic progression. J. Med. Virol. 82, 311–320. doi:
10.1002/jmv.21676
Kalantari, M., Garcia-Carranca, A., Morales-Vazquez, C. D., Zuna, R., Montiel, D.
P., Calleja-Macias, I. E., et al. (2009). Laser capture microdissection of cervical
human papillomavirus infections: copy number of the virus in cancerous and
normal tissue and heterogeneous DNAmethylation. Virology 390, 261–267. doi:
10.1016/j.virol.2009.05.006
Kalantari, M., Osann, K., Calleja-Macias, I. E., Kim, S., Yan, B., Jordan, S., et al.
(2014). Methylation of human papillomavirus 16, 18, 31, and 45 L2 and
L1 genes and the cellular DAPK gene: considerations for use as biomark-
ers of the progression of cervical neoplasia. Virology 448C, 314–321. doi:
10.1016/j.virol.2013.10.032
Kaminsky, Z., and Petronis, A. (2009). Methylation SNaPshot: a method for the
quantification of site-specific DNA methylation levels. Methods Mol. Biol. 507,
241–255. doi: 10.1007/978-1-59745-522-0_18
Kim, J. H., Dhanasekaran, S. M., Prensner, J. R., Cao, X., Robinson, D.,
Kalyana-Sundaram, S., et al. (2011). Deep sequencing reveals distinct pat-
terns of DNA methylation in prostate cancer. Genome Res. 21, 1028–1041. doi:
10.1101/gr.119347.110
Komori, H. K., Lamere, S. A., Torkamani, A., Hart, G. T., Kotsopoulos, S., Warner,
J., et al. (2011). Application of microdroplet PCR for large-scale targeted
bisulfite sequencing. Genome Res. 21, 1738–1745. doi: 10.1101/gr.116863.110
Krueger, F., and Andrews, S. R. (2011). Bismark: a flexible aligner and methy-
lation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571–1572 doi:
10.1093/bioinformatics/btr167
Ku, C. S., Naidoo, N., Wu, M., and Soong, R. (2011). Studying the
epigenome using next generation sequencing. J. Med. Genet. 48, 721–730. doi:
10.1136/jmedgenet-2011-100242
Laird, P. W. (2010). Principles and challenges of genomewide DNA methylation
analysis. Nat. Rev. Genet. 11, 191–203. doi: 10.1038/nrg2732
Langmead, B., Trapnell, C., Pop, M., and Salzberg, S. L. (2009). Ultrafast and
memory-efficient alignment of short DNA sequences to the human genome.
Genome Biol. 10:R25. doi: 10.1186/gb-2009-10-3-r25
Li, L. C., and Dahiya, R. (2002). MethPrimer: designing primers for methy-
lation PCRs. Bioinformatics 18, 1427–1431. doi: 10.1093/bioinformatics/
18.11.1427
Li, N., Franceschi, S., Howell-Jones, R., Snijders, P. J., and Clifford, G. M.
(2011). Human papillomavirus type distribution in 30,848 invasive cervi-
cal cancers worldwide: variation by geographical region, histological type
and year of publication. Int. J. Cancer 128, 927–935. doi: 10.1002/ijc.
25396
Lorincz, A. T., Brentnall, A. R., Vasiljevic, N., Scibior-Bentkowska, D., Castanon,
A., Fiander, A., et al. (2013). HPV16 L1 and L2 DNA methylation predicts high
grade cervical intraepithelial neoplasia in women with mildly abnormal cervical
cytology. Int. J. Cancer. 133, 637–644. doi: 10.1002/ijc.28050
Mirabello, L., Schiffman, M., Ghosh, A., Rodriguez, A. C., Vasiljevic, N.,
Wentzensen, N., et al. (2013). Elevated methylation of HPV16 DNA is associ-
ated with the development of high grade cervical intraepithelial neoplasia. Int.
J. Cancer 132, 1412–1422. doi: 10.1002/ijc.27750
Mirabello, L., Sun, C., Ghosh, A., Rodriguez, A. C., Schiffman, M., Wentzensen,
N., et al. (2012). Methylation of human papillomavirus type 16 genome and
risk of cervical precancer in a Costa Rican population. J. Natl. Cancer Inst. 104,
556–565. doi: 10.1093/jnci/djs135
Nejman, D., Straussman, R., Steinfeld, I., Ruvolo, M., Roberts, D., Yakhini, Z., et al.
(2014). Molecular rules governing de novo methylation in cancer. Cancer Res.
74, 1475–1483. doi: 10.1158/0008-5472.CAN-13-3042
Oates, N. A., van Vliet, J., Duffy, D. L., Kroes, H. Y., Martin, N. G., Boomsma,
D. I., et al. (2006). Increased DNAmethylation at the AXIN1 gene in a monozy-
gotic twin from a pair discordant for a caudal duplication anomaly. Am. J. Hum.
Genet. 79, 155–162. doi: 10.1086/505031
Piyathilake, C. J., Macaluso, M., Alvarez, R. D., Chen, M., Badiga, S., Edberg, J. C.,
et al. (2011). A higher degree of methylation of the HPV 16 E6 gene is asso-
ciated with a lower likelihood of being diagnosed with cervical intraepithelial
neoplasia. Cancer 117, 957–963. doi: 10.1002/cncr.25511
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., and Wacholder S.
(2007). Human papillomavirus and cervical cancer. Lancet 370, 890–907. doi:
10.1016/S0140-6736(07)61416-0
Schiffman, M., and Wentzensen, N. (2013). Human papillomavirus infec-
tion and the multistage carcinogenesis of cervical cancer. Cancer
Epidemiol. Biomarkers Prev. 22, 553–560. doi: 10.1158/1055-9965.EPI-
12-1406
www.frontiersin.org June 2014 | Volume 5 | Article 150 | 7
Sun et al. NGS HPV DNA methylation analyses
Schmieder, R., and Edwards, R. (2011). Quality control and preprocessing of
metagenomic datasets. Bioinformatics 27, 863–864. doi: 10.1093/bioinformat-
ics/btr026
Sun, C., Reimers, L. L., and Burk, R. D. (2011). Methylation of HPV16 genome
CpG sites is associated with cervix precancer and cancer. Gynecol. Oncol. 121,
59–63. doi: 10.1016/j.ygyno.2011.01.013
Taylor, K. H., Kramer, R. S., Davis, J. W., Guo, J., Duff, D. J., Xu, D., et al.
(2007). Ultradeep bisulfite sequencing analysis of DNA methylation patterns
in multiple gene promoters by 454 sequencing. Cancer Res. 67, 8511–8518. doi:
10.1158/0008-5472.CAN-07-1016
Tost, J., and Gut, I. G. (2007a). DNA methylation analysis by pyrosequencing. Nat.
Protoc. 2, 2265–2275. doi: 10.1038/nprot.2007.314
Tost, J., and Gut, I. G. (2007b). Analysis of gene-specific DNA methylation pat-
terns by pyrosequencing technology. Methods Mol. Biol. 373, 89–102. doi:
10.1038/nprot.2007.314
Turan, T., Kalantari, M., Calleja-Macias, I. E., Cubie, H. A., Cuschieri, K.,
Villa, L. L., et al. (2006). Methylation of the human papillomavirus-18 L1
gene: a biomarker of neoplastic progression? Virology 349, 175–183. doi:
10.1016/j.virol.2005.12.033
Turan, T., Kalantari, M., Cuschieri, K., Cubie, H. A., Skomedal, H., and Bernard,
H. U. (2007). High-throughput detection of human papillomavirus-18 L1 gene
methylation, a candidate biomarker for the progression of cervical neoplasia.
Virology 361, 185–193. doi: 10.1016/j.virol.2006.11.010
Wentzensen, N., Sun, C., Ghosh, A., Kinney, W., Mirabello, L., Wacholder, S., et al.
(2012). Methylation of HPV18, HPV31, and HPV45 genomes and cervical
intraepithelial neoplasia grade 3. J. Natl. Cancer Inst. 104, 1738–1749. doi:
10.1093/jnci/djs425
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 05 March 2014; paper pending published: 21 March 2014; accepted: 08 May
2014; published online: 03 June 2014.
Citation: Sun C, McAndrew T, Smith BC, Chen Z, FrimerM and Burk RD (2014)
Characterization of HPV DNA methylation of contiguous CpG sites by bisulfite treat-
ment and massively parallel sequencing—the FRAGMENT approach. Front. Genet.
5:150. doi: 10.3389/fgene.2014.00150
This article was submitted to Epigenomics and Epigenetics, a section of the journal
Frontiers in Genetics.
Copyright © 2014 Sun, McAndrew, Smith, Chen, Frimer and Burk. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Genetics | Epigenomics and Epigenetics June 2014 | Volume 5 | Article 150 | 8
